Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Genor Biopharma Holdings's PB Ratio or its related term are showing as below:
FRA:67N0'
s PB Ratio Range Over the Past 10 Years
Min: 0.17 Med: 0.61 Max: 47.28
Current: 1.32
During the past 7 years, Genor Biopharma Holdings's highest PB Ratio was 47.28. The lowest was 0.17. And the median was 0.61.
FRA:67N0's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.785
vs FRA:67N0: 1.32
During the past 12 months, Genor Biopharma Holdings's average Book Value Per Share Growth Rate was -4.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -24.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 14.40% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Genor Biopharma Holdings was 103.30% per year. The lowest was -28.50% per year. And the median was 10.80% per year.
Back to Basics: PB Ratio
Genor Biopharma Holdings (FRA:67N0) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Genor Biopharma Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genor Biopharma Holdings PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Genor Biopharma Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Genor Biopharma Holdings (FRA:67N0) has a PB Ratio of 1.32 as of Jul. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Genor Biopharma Holdings and its competitors. This is 116% above median its historical median of 0.61. Over the past decade, Genor Biopharma Holdings' PB Ratio has ranged from 0.17 to 47.28.
Is Genor Biopharma Holdings' PB Ratio too high?
Genor Biopharma Holdings' current PB Ratio of 1.32 is 116% above median its 10-year median of 0.61. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 47.28. The Biotechnology industry median PB Ratio is 2.79. Genor Biopharma Holdings' value of 1.32 is 52.6% below this industry median. Overall, Genor Biopharma Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Genor Biopharma Holdings' PB Ratio compare to VRTX and REGN?
Genor Biopharma Holdings' PB Ratio of 1.32 can be compared against companies in the Biotechnology industry. The industry median PB Ratio is 2.79. Genor Biopharma Holdings' value of 1.32 is 52.6% below this benchmark. Historically, Genor Biopharma Holdings' own PB Ratio has ranged from 0.17 to 47.28 over the past decade. While the company's 10-year median is 0.61 vs. the industry median of 2.79, Genor Biopharma Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genor Biopharma Holdings's current PB Ratio of 1.32 is 52.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Genor Biopharma Holdings and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genor Biopharma Holdings's current PB Ratio is 1.32, which is 116% above median its own 10-year median of 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genor Biopharma Holdings stock overvalued right now?
Genor Biopharma Holdings (FRA:67N0) has a current PB Ratio of 1.32. The current PB Ratio is 1.32, which is 116% above median its 10-year median of 0.61 and 52.6% below the Biotechnology industry median of 2.79. Genor Biopharma Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Genor Biopharma Holdings (FRA:67N0), the current PB Ratio is 1.32 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
22GF Score
Get the complete analysis for FRA:67N0
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:67N0 has been successfully added to your 
